Bone morphogenetic protein 4 (BMP4) has potential as an anticancer agent. Recent studies have suggested that BMP4 inhibits the survival of cancer stem cells (CSCs) of neural and colon cancers. Here, we showed that BMP4 paracrinically inhibited tumor angiogenesis via the induction of Thrombospondin-1 (TSP1), and consequently suppressed tumor growth in vivo. Although HeLa (human cervical cancer), HCI-H460-LNM35 (highly metastatic human lung cancer) and B16 (murine melanoma) cells did not respond to the BMP4 treatment in vitro, the growth of xeno-and allografts of these cells was suppressed via reductions in tumor angiogenesis after intraperitoneal treatment with BMP4. When we assessed the mRNA expression of major angiogenesis-related factors in grafted tumors, we found that the expression of TSP1 was significantly upregulated by BMP4 administration. We then confirmed that BMP4 was less effective in suppressing the tumor growth of TSP1-knockdown cancer cells. Furthermore, we found that BMP4 reduced vascular endothelial growth factor (VEGF) expression in vivo in a TSP1-dependent manner, which indicates that BMP4 interfered with the stabilization of tumor angiogenesis. In conclusion, the BMP4/TSP1 loop paracrinically suppressed tumor angiogenesis in the tumor microenvironment, which subsequently reduced the growth of tumors. BMP4 may become an antitumor agent and open a new field of antiangiogenic therapy.
INTRODUCTION
Recent studies have shown that bone morphogenetic protein 4 (BMP4) can directly exert an effect on cancer cells themselves, or on CSCs, inducing growth inhibition, cell cycle arrest, senescence, apoptosis or differentiation. [1] [2] [3] [4] [5] [6] Regarding the effect of BMP4 on tumors, BMP4 was shown to induce differentiation in CSCs and suppress tumor growth in glioblastoma and colon cancer. 4, 5 Zhou et al. 7 reported that BMP4 inhibited proliferation and induced apoptosis in glioma stem cells. Because BMP4 is originally expressed in the neural crest during the development of the embryo, 8 it may play a particular role in the regulation of neural cancer cells. In contrast, some colon cancer cell lines were resistant to BMP4 treatment in vitro. 9 Other studies have shown that BMP4 facilitated the dissemination of melanoma cells from primary tumors, 10 attenuated apoptosis in cerebellar primitive neuro-ectodermal tumor cell lines, 11 upregulated proto-oncogenes in ovarian cancer cell lines, 12 and stimulated the proliferation of osteosarcoma cells. 13 However, most of these studies explored the effect of BMP4 on the cancer cells themselves and did not consider the effect of BMP4 on the tumor microenvironment, especially with respect to tumor angiogenesis in an in vivo context.
We previously reported that BMP4 induced apoptosis in endothelial cells. 14, 15 BMP4 was shown to be originally essential to the development of organisms, such that the deletion of BMP4 results in embryonic lethality. 16 We demonstrated that BMP4 was required to remove the capillary network from the rat pupil to produce a clear cornea during the normal development of rat eyes. 14 We subsequently revealed that BMP4 induced apoptosis in endothelial cells. 15 Indeed, heterozygotic deletion of BMP4 resulted in ocular abnormalities including opacification of the human lens. 17, 18 Because BMP4 has been shown to regulate vascular remodeling, 19 we postulated that BMP4 may reduce tumor endothelial growth. BMP4 is a member of the Transforming Growth Factor-b (TGF-b) superfamily, and may have a similar function to TGF-b. Komuro et al. 20 reported that a disruption in TGF-b signaling in diffuse-type gastric carcinoma models accelerated tumor growth through increased tumor angiogenesis, as a result of decreased thrombospondin-1(TSP1) expression. Thus, we hypothesized that BMP4 may regulate tumor angiogenesis during tumor development and could ultimately suppress tumor growth.
RESULTS

BMP4 signaling via Smad1,5 did not inhibit the proliferation of HeLa, LNM35 or B16 cells in vitro
To investigate whether BMP4 directly suppresses cell growth, we performed clonogenic and colony assays for HeLa (human cervical cancer), HCI-H460-LNM35 (highly metastatic human lung cancer), B16 (murine melanoma), LLC (murine Lewis lung carcinoma), GOTO (human neuroblastoma) and T98G (human glioblastoma) cells with or without BMP4 (100 ng/ml) in an appropriate medium containing 10% fetal bovine serum for 7-10 days. We found that the proliferation of HeLa, LNM35 and B16 cells was not inhibited by BMP4 (Figures 1 a-c) . On the other hand, the proliferation of LLC was reduced by B30-40% with the BMP4 treatment in clonogenic assay (Figure 1d ). The proliferation of GOTO and T98G, both neural cancer cell lines, was also markedly reduced (Supplementary Figure S1A and B) .
Because phosphorylation of Smad1,5 (p-Smad1,5) is the main signaling pathway of BMP4, we examined p-Smad1,5 levels in tumor cells. We then confirmed that BMP4 signaling exerted its effect through the p-Smad1,5 in cancer cells (Figures 2a-c , and Supplementary Figure S1C) . These results suggest that BMP4 could strongly stimulate cancer cells via p-Smad1,5 signaling; however, this did not suppress the growth of LNM35, HeLa or B16 cells in vitro.
From the above results, we selected these cell lines that did not have any direct growth effect upon BMP4 treatment in order to focus on the angiogenic effect of BMP4 in the tumor microenvironment.
Because TSP1 is known to induce apoptosis in endothelial cells and is a strong antiangiogenic factor, 21 we focused on the relationship between BMP4 and TSP1 in the suppression of tumor angiogenesis. In HeLa and LNM35 cell lines, kinetic analysis of real-time PCR revealed that human TSP1 expression temporarily increased after stimulation with BMP4 ( Supplementary Figures S2A and B) . Although the TSP1 mRNA increase in HeLa cells was only 1.5-fold at 2 and 4 h after the BMP4 treatment, we confirmed that the secreted TSP1 protein level was significantly increased in the cultured medium of HeLa cell line (Supplementary Figure S2C) . Figure 1 . Clonogenic (monolayer) and colony (anchorage-independent) assays were performed to assess the proliferation ability of cells in culture in the presence or absence of BMP4 (100 ng/ml). (a, b) Proliferation of human epithelial cancer cell lines, HeLa (cervical cancer) and LNM35 (highly metastatic lung cancer), were not significantly suppressed by BMP4. (c, d) Murine cancer cell lines, B16 (melanoma; mesenchymal cancer) and LLC (Lewis lung cancer), were also treated with BMP4 (100 ng/ml): proliferation of LLC was suppressed by 30-40% in clonogenic assay, whereas that of B16 was not affected. n.s., not significant. **Po0.01.
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We confirmed that small interfering RNA (siRNA)/TSP1 (si-1) was the most effective among the three kinds of siRNAs for TSP1 knockdown (Supplementary Figure S2D) and that siRNA/TSP1 (si-1) reduced TSP1 protein expression by western blot analysis (Supplementary Figure S2E) . Next, we found that p-Smad1,5 levels in response to stimulation by BMP4 was not affected by TSP1 knockdown in HeLa and LNM35 cells (Figures 2d and e) . These results suggest that BMP4 modulates TSP1 expression downstream of BMP4 signaling in both HeLa and LNM35 cells.
BMP4 inhibited the proliferation of endothelial cells in vitro Because we assumed that tumor endothelial cells may share some intrinsic characteristics with normal endothelial cells, we used HUAECs (human arterial endothelial cells), HUVECs (human venous endothelial cells) and HMVEC-dLy-Neo (human lymphatic endothelial cells; HMVECs) to investigate the effect of BMP4 on endothelial cells.
Colony assays for 2 weeks revealed that proliferation of the endothelial cells was inhibited by BMP4 (100 ng/ml; Figure 3a) . The expression of p-Smad1,5 was detected in HUVECs and HMVECs after BMP4 stimulation, but at lower levels than that in cancer cells (Figure 3b) . However, the expression of Id1, which is a main target gene of BMP4, 22, 23 was significantly increased by BMP4 treatment in both HUVEC and HMVEC cell lines (Figure 3c ). The BMP4 receptors, BMPR-1A, -1B and -2, were expressed in HUAECs, HUVECs and HMVECs; their expression levels were highest in HMVECs (Supplementary Figure S3) . Moreover, the phosphorylation of Extracellular signal-regulated kinases 1 and 2 (ERK1,2) was found in HUVECs, but not in HMVECs (Figure 3b ). Phosphorylation of ERK1,2 generally transduces proliferation signals in the cells; 24 therefore, the Smad-dependent pathway may mediate the inhibition of HUVEC growth.
A matrigel assay revealed that BMP4 inhibited tube formation; HMVECs in particular were more sensitive than HUVECs to the lowdose BMP4 treatment (Figure 3d ). These results suggest that BMP4 directly suppresses proliferation of endothelial cells in vitro; this mechanism may also be involved in tumor endothelial cells.
On the other hand, BMP4 stimulation did not induce TSP1 mRNA expression in HUAECs, HUVECs or HMVECs (Supplementary Figure S4) . This indicated that BMP4 treatment directly inhibited the growth of tumor endothelial cells; however, endothelial cells may not be suppressed by the autocrine effect of TSP1.
BMP4 inhibited tumor angiogenesis and consequently suppressed the growth of BMP4-resistant cancer cells in vivo To investigate whether BMP4 exerts a direct antiangiogenic effect in tumor microenvironment, we employed a well-established xenograft model. Tumor angiogenesis was evident between days 2 and 4, with the formation of CD31
þ -blood vessels in our mouse experimental model. 25 Hypoxia-inducible proangiogenic factors, such as VEGF, 26 were highly expressed in avascular tumor tissue on day 2; TSP1 was also significantly upregulated in avascular tissue on day 2. 25 Therefore, we considered that injecting BMP4 on day 2 would reveal the effect of BMP4 on the tumor angiogenic switch. We then found that the growth of tumors treated intraperitoneally with BMP4 (henceforth, referred to as BMP4-i.p. (e, f) TSP1 was knocked down by siRNA in HeLa and LNM35 cells; these cells were then stimulated by BMP4. Western blotting data showed that BMP4 signaling was not influenced by TSP1 knockdown. In addition, TSP1 knockdown did not affect p-ERK1,2 in HeLa cells.
BMP4/TSP1 loop paracrinically suppressed tumor angiogenesis R Tsuchida et al Figure S5 ). These results indicate that BMP4 transduced its signal into the cancer cells of xenografts by the end point (day 20). We simultaneously confirmed that BMP4 did not damage the somatic vascular systems of the brains and lungs of mice (Supplementary Figure S6) , which suggests that BMP4 is effective against de novo angiogenesis, and thus suppresses tumor angiogenesis.
To examine the molecular mechanism of the antitumor activity of BMP4, we investigated the expression of angiogenesis-related gene expression by performing quantitative PCR of mRNA extracted from grafted tumors (Supplementary Figure S7) . We found that the mRNA expression of human TSP1 was markedly higher in BMP4-i.p.-HeLa and -LNM35 tumors than in control tumors (Figures 4g and h ). In addition, the expression of mouse Tsp1 was also significantly different between control and BMP4-i.p.-tumors (Figure 4i ).
BMP4-mediated inhibition of tumor angiogenesis was dependent on the expression of TSP1 in tumor cells To confirm whether tumor-derived TSP1 was involved in tumor suppression induced by BMP4, we performed transient knockdown of human TSP1 (hTSP1) using siRNA in HeLa cells and grafted these cells subcutaneously into mice. Control mice received grafts of HeLa cells that had been transfected with control siRNA. We found that the ability of BMP4 to inhibit tumor growth was abrogated by silencing the expression of TSP1 (Figure 5a) . However, the effect of siRNA/TSP1 generally would fade away Figure S8B) , BMP4 finally suppressed the growth of the siRNA/TSP1 tumor as well after day 15 (data not shown). Hence, we injected the atelocollagen and siRNA/TSP1 mixture on day 9 to sustain the effect of TSP1 knockdown, wrapping the xenografts in the subcutaneous tissue of mice. Under these conditions, we found that the effect of TSP1 knockdown continuously interfered with the suppression of tumor growth by BMP4 by the end point of the experiment (day 21) (Figure 5b ). These results suggest that the ability of BMP4 to inhibit tumor growth was abrogated by TSP1 knockdown.
We also found that the protein level of human VEGF was decreased in the BMP4-treated HeLa and LNM35 xenografts (Figures 5d and e) , suggesting that BMP4 might directly inhibit VEGF secretion of tumor cells. Our findings that BMP4 treatment inhibited VEGF secretion in HeLa and LNM35 cell lines in vitro (Supplementary Figure S9A) further indicate the anti-VEGF activity of BMP4. In addition, the expression of mouse-VEGF receptors (Flt1 and Flk1), which are host receptors for VEGF, was not significantly altered independently of BMP4 treatment or TSP1 knockdown (Supplementary Figure S9B) . Considering that human VEGF could transmit proangiogenic signal in mouse, 28 we consider that BMP4-mediated reduction in VEGF expression played a significant role in the antitumor activity in the mouse xenografts.
Taken together, the antitumor effect of BMP4 has two aspects: direct growth inhibition of endothelial cells plus paracrine increase in TSP1 and concomitantly decrease in VEGF, leading to an antiangiogenic effect in the tumor microenvironment.
DISCUSSION
In the present study, we showed that BMP4, administered intraperitoneally, inhibited tumor angiogenesis, and resulted in the suppression of tumor growth in vivo. To date, the effects of BMP4 on tumors have been controversial; however, the methods used to assess the role of BMP4 treatments on cancer cells have varied, and may partly explain the conflicting findings; 29 some investigators transfected vectors expressing BMP4 or its receptors into cancer cells and observed the growth of tumors, 1, 30, 31 whereas others pretreated cancer cells with BMP4 and then transplanted them into mice. The distinction of our study is that, firstly, we focused on the role of BMP4 in tumor angiogenesis in vivo, and, secondly, we administrated BMP4 (100 ng/g body weight per mouse) systematically via the intra-abdominal cavity after tumor grafting. Our results showed that BMP4-treatment inhibited the early stage of the angiogenic switch.
BMP4 is also known as an important regulator of normal embryonic stem cells, 32, 33 adult stem cells 32 and CSCs in neural and colon cancers. 4, 5 Generally, established cancer cell lines contain B3% CSC-like cells. 34, 35 The cell lines that we used in the present study may have also contained a small number of CSC-like cells. However, BMP4 did not affect cell proliferation in non-neural cancer cell lines such as HeLa and LSM35 cells in vitro. Hence, we focused on the effect of BMP4 in the tumor microenvironment using these cell lines.
We investigated the efficacy of the BMP4 treatment using normal cultured human endothelial cells instead of tumor endothelial cells. Because Hida et al. 36 claimed that tumor endothelial cells were different from normal endothelial cells, we attempted to sort tumor endothelial cells labeled with CD31 þ using flow cytometry (FACSAria II, BD Biosciences, San Jose, CA, USA) from B1 cm 3 sized xenografts appropriately treated with collagenase. 36 The number of CD31 þ tumor endothelial cells was almost 100 (data not known), and these were not able to be cultured and were not used for the experiments performed in the present study. However, we found that BMP4 inhibited the proliferation of normal endothelial cells, particularly in HUVECs and HMVECs. This result may indicate that tumor endothelial cells could also be sensitive to BMP4 and, indeed, we found that CD31 þ -vessels were significantly reduced in BMP4-i.p.-tumors.
TSP1 is known as an inhibitor of proliferation in endothelial cells, 21 and it induces apoptosis 37 and suppresses the cell cycle 38 of these cells. Furthermore, TSP1 expression in stroma suppressed tumor growth 39 and may be a new antiangiogenic agent for the treatment of solid tumors. 40 However, the interplay between BMP4 and TSP1 is not yet fully understood. In our in vitro treatments of cultured cancer cell lines with BMP4, BMP4 upregulated TSP1. On the other hand, BMP4 stimulation of HUAECs, HUVECs and HMVECs for 3 days did not induce TSP1 expression. Thus, BMP4 stimulated cancer cells, but not endothelial cells, to induce TSP1 expression. The angiogenic switch is turned on in the early period (days 2-4) in our mouse xenograft model; 25, 41, 42 therefore, we first performed siRNA transfection to silence TSP1, and then performed the grafts. Because an RNA silencing approach using siRNA treatment is generally continued for 7-10 days, 27 we employed the atelocollagencontinuously siRNA/TSP1 delivery system after day 9. Then, we confirmed that TSP1-knockdown in grafted cancer cells resulted in the abrogation of the effect of BMP4. Thus, BMP4 and TSP1 paracrinically suppressed tumor angiogenesis in vivo.
VEGF is a potent angiogenic and tumor-promoting growth factor. Inhibition of VEGF secreted from cancer cells was found to have antitumor activity in various types of tumors because of multiple mechanisms including the regulation of endothelial cell growth and migration 43 as well as tumor-associated macrophage infiltration. 25, 42, 44 We found that the level of human VEGF protein in HeLa and LNM35 xenografts was significantly decreased in BMP4-treated tumors. Moreover, we ascertained that VEGF was decreased in the supernatant of both HeLa and LNM35 cell lines after treatment with BMP4 (100 ng/ml) for 16 h in vitro. We suggest that BMP4-mediated decrease in VEGF secretion contributed to tumor growth inhibition in a TSP1-dependent manner, because of the following reasons. First, it is unlikely that inhibition of VEGF reduced autocrine growth of cancer cells, because the protein level of VEGF receptors in cancer cells is extremely low. 34, 45 Autocrine signaling of VEGF/VEGF receptors mainly regulates proliferation or drug resistance of cancer cells, 34, 45 and may contribute less to tumor angiogenesis. Second, it is most likely that the paracrine effect of VEGF on endothelial cells played a major role for tumor angiogenesis in vivo, because the expression of host VEGF receptors in mice carrying the HeLa xenografts was not altered independently of BMP4 treatment or TSP1 knockdown. Under these circumstances, where VEGF from cancer cells was decreased by BMP4 and the expression of VEGF receptors by the host was not changed, stabilization of tumor angiogenesis could be interfered. The stabilization or vessel normalization is one of the mechanisms of tumor growth inhibition by anti-VEGF agents. 46 We suggest that BMP4 mediated anti-VEGF activity and consequently affected vessel stabilization, resulting in tumor growth inhibition.
Taken together, BMP4-mediated antitumor activity had multiple mechanisms that include direct effect on VEGF secretion, as well as the effect on TSP1 expression. Considering that BMP4 could not efficiently inhibit tumor angiogenesis via VEGF secretion in the absence of TSP1 expression, the BMP4/TSP1 loop may play an important role in the regulation of angiogenesis in the tumor microenvironment.
Interestingly, we found that ERK1,2 was phosphorylated in response to BMP4 stimulation in LNM35, HeLa cells and even HUVECs. Generally, ERK1,2 signaling is considered to induce cell proliferation, and its signaling pathway is activated by various growth factors and cytokines, 24 including BMP4. 47, 48 Recently, Chiu et al. 6 revealed that when BMP4 activated ERK1,2 signaling via BMP receptor II (Smad-independent pathway), human hepatocarcinoma cells were stimulated to proliferate and migrate. On the other hand, when BMP4 phosphorylated Smad1,5 through the BMP receptor IA (Smad-dependent pathway), the proliferation of these cells was inhibited. Moreover, these authors showed that cancer cells with BMP receptor IA knockdown were significantly less tumorigenic in vivo in xenograft studies. 6 These effects may be based on an autocrine system in cancer cells. In our study, the strong stimulation of p-Smad1,5 in cancer cells indicated that there was paracrine stimulation between cancer cells and tumor endothelial cells where TSP1, induced by BMP4 stimulation, regulated the tumor microenvironment, and particularly the behavior of tumor endothelial cells, resulting in the suppression of tumor angiogenesis in vivo.
Although TSP1 is known as an antiangiogenic factor, the overexpression of TSP1 alone did not influence tumor growth. 49 We therefore propose that TSP1 is able to act under BMP4 regulation, and thereby the BMP4/TSP1 loop inhibits tumor angiogenesis, resulting in the paracrinal suppression of tumor growth. BMP4 has strong potential as an anticancer agent; however, further investigations are required before its use in a clinical context.
MATERIALS AND METHODS
Cell culture
HeLa, T98G, GOTO, B16, LLC, M059J (human glioblastoma) and A204 (human rhabdomyosarcoma) cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Human highly metastatic lung carcinoma HCI-H460-LNM35 (henceforth known as LNM35) was established by Kozaki et al. 50 Cells were cultured in Dulbecco's modified Eagle's medium (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum. HUAECs, HUVECs and neonatal normal human dermal lymphatic microvascular endothelial cells (HMVEC-dLy-Neo; henceforth known as HMVECs) were purchased from Lonza (Takara Bio Inc., Shiga, Japan) and grown in EBM2 medium (Lonza). These cell lines were maintained at 37 1C with 5% CO 2 .
Colony formation and Clonogenic assays After BMP4 treatment, cells were suspended in Dulbecco's modified Eagle's medium (for cancer cells) or EBM2 (for endothelial cells) containing 0.6% methylcellulose (Wako, Osaka, Japan), supplemented with 10% fetal bovine serum (for cancer cells) or 5% fetal bovine serum (for endothelial cells) and seeded into six-well plates at a density of 1 Â 10 4 cells per well, in BMP4/TSP1 loop paracrinically suppressed tumor angiogenesis R Tsuchida et al triplicate. No-BMP4 treatment cells were seeded at the same number and used as control colonies. After 10-14 days, anchorage-independent colonies were counted using a microscope. For Clonogenic assay (anchorage-dependent, monolayer colonies), after BMP4 treatment, cells were seeded out in appropriate dilutions to form colonies in 2 weeks. Colonies were fixed with 100% alcohol, stained with crystal violet (0.5% w/ v) and counted using a microscope.
Matrigel net-like formation assay
HUVECs and HMVECs were incubated for 8 h on top of a matrigel layer. These endothelial cells were treated with serum-free medium containing BMP4 (100 or 200 ng/ml), and then plated in growth factor-free matrigel (BD Bioscience, San Jose, CA, USA). The area of net-like formation was quantified using angiogenesis image analyzer (Kurabo, Osaka, Japan).
Gene expression analysis using real-time PCR
Total RNA was extracted from cells using Isogen reagent (Nippon Gene, Toyama, Japan), converted to complementary DNA with Prime Script reverse transcriptase (Takara, Shiga, Japan) as per the manufacturer's instructions and used for quantitative real-time PCR amplification using SYBR Green (Takara). Primer sequences are summarized in Supplementary  Table S1 .
Small interfering RNA siRNAs were designed against hTSP1 and obtained commercially (Invitrogen, Life Technologies, Tokyo, Japan). In this study, three sequences of siRNA were used against hTSP1, designated as siRNA-1 (si-1):
0 and siRNA-3 (si-3): 5 0 -UUCUUCAUCUGCCUCAGGGAUGCCA-3 0 . Cells were transfected with hTSP1 siRNAs or negative (scramble)-control siRNA using Lipofectamine RNAi MAX transfection reagent, according to the manufacturer's instructions (Invitrogen, Life Technologies). The ability of siRNA to inhibit hTSP1 expression was accessed 48 h post transfection. The most effective siRNA to knockdown TSP1 expression was siRNA1 (si-1) (Supplementary Figure S2D) , and we confirmed that si-1 significantly reduced TSP1 protein by western blotting analysis (Supplementary Figure S2E) . Then, we used si-1 for following experiments.
Western blotting
Cell lysates were applied to a 10 or 12.5% polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (Invitrogen, Tokyo, Japan). The membrane was incubated with anti-p-Smad1,5, p-ERK1,2, ERK1,2 p-AKT, AKT, Smad1 (Cell Signaling Technology, Inc., Boston, MA, USA), Vinculin and Actin antibody (Millipore, Temecula, CA, USA), followed by horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Buckinghamshire, UK). Signals were detected using enhanced chemiluminescence detection reagents (GE Healthcare) and images were acquired with a luminescent image analyzer (LAS3000, Fuji Photo Film Co., Ltd, Tokyo, Japan). Signal visualization was partly performed by using a 5-bromo-4-chloroindolyl phosphate (BCIP) and nitroblue tetrazolium (NBT) detection system (Promega, Madison, WI, USA). The quantification of the blot signal was used by ImageJ software (NIH, Bethesda, MD, USA).
Animal studies and tumor xeno-and allografts All animal care procedures were in accordance with institutional guidelines approved by Tokyo Medical and Dental University (Tokyo, Japan). Eightweek-old mice were anesthetized and 1 Â 10 7 HeLa, LNM35 and B16 cells were injected subcutaneously into the back skin of C.B17/Icr-scid Jcl scid/ scid mice for HeLa and LNM35 (xenografts), or of C57BL/6J mice for B16 (allograft). Both human and mouse BMP4 (R&D Systems, Inc., Minneapolis, MN, USA) were used for human cancer cell lines (HeLa and LNM35), and for B16 (mouse melanoma), reciprocally. BMP4 (100 ng per g body weight) was administrated intraperitoneally on day 2, when the angiogenic switch is turned on in xenograft tumors in our mouse model. 25, 42 As recommended by the manufacturer, both human and murine BMP4 were dissolved in sterile water containing 0.1% bovine serum albumin and 4 mM HCl; these solutions were injected intraperitoneally to control mice carrying tumors. The same volume of the carrier used to dissolve BMP4 was administered intraperitoneally in controls. To confirm the effect of siRNA/TSP1 for more than 10 days, we injected 200 ml of the atelocollagen (AteloGene; Koken Co., Ltd, Tokyo, Japan) and siRNA/TSP1 mixture on day 9, wrapping the xenograft tumors in subcutaneous tissue. Tumor volume was measured every 2-3 days from day 5 and the results were analyzed using Student's t-test.
Immunofluorescence and immunohistochemical staining
Freshly frozen tumor samples were sectioned into 14-mm-thick slices using a Cryostat (Leica, Wetzlar, Germany) and stained with hamster anti-CD31 antibody (BD Biosciences). Sections were incubated with the appropriate secondary antibody and nuclear-staining dye To-Pro-3 (Invitrogen, Life Technologies) and were then analyzed using a confocal microscope (Radiance 2000; Bio-Rad, Hercules, CA, USA). The formalin-fixed, paraffinembedded xenograft tumors were cut to 4 mm sections and deparaffinized in xylene. The sections were incubated in 0.3% H 2 O 2 for 10 min to inactivate endogenous peroxidase, followed by washing in phosphatebuffered saline. Phospho-Smad1,5 (Cell Signaling Technology Inc.) was used as a primary antibody. A 3,3 0 -diaminobenzidine peroxytrichloride substrate solution (DAKO, Tokyo, Japan) was used to visualize the p-Smad1,5-positive signal.
Immunoassay using enzyme-linked immunosorbent assay system Human TSP-1 and human VEGF in the supernatant of both HeLa and LNM35 xenografts were measured by the quantitative sandwich enzyme immunoassay technique using a Quantikine kit (R&D Systems) according to the manufacturer's instructions. Culture medium of HeLa cell line without serum was collected after 6 h of human BMP4 stimulation. Optical density was determined using a microplate reader (iMark Microplate reader, Bio-Rad, Tokyo, Japan).
Statistical analysis
All values are expressed as means±s.d. The statistical significance of differences between two groups was evaluated using Student's t-test. Statistical significance was accepted at Po0.05, unless otherwise indicated.
